Shentu, Yue
Merck & Co., Inc., Rahway, NJ, USA (United States) · The University of Sydney · Okayama University · Tel Aviv University · Hospital Universitario Insular de Gran Canaria · Kingston General Hospital · Westmead Hospital · Sidney Kimmel Comprehensive Cancer Center
2 papers on CoChatORCID 0000-0002-9547-1387
Most cited papers
- Verified
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 10,089
- Verified
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 6,449
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free